Articles

  1. Bridging Studies For Producer Cell Line Adoption: Regulatory And Development Perspectives 6/1/2026

    Explore how analytical comparability, risk assessment, and bridging strategies can support a smooth and compliant platform transition.

  2. Strategic CDMO Partnerships Begin By Unraveling The Complexities 5/20/2026

    Selecting the right CDMO is critical for pharmaceutical sponsors. To avoid pitfalls, sponsors should evaluate a CDMO's capacity, technical capabilities, quality metrics (like CAPA effectiveness and deviation times), financial stability, and talent retention. Establishing strong communication, supply chain transparency, and routine quality audits also helps ensure a successful, long-term partnership.

  3. Highly Potent Active Pharmaceutical Ingredients 5/19/2026

    Empower safer, faster development of complex therapeutics by partnering with an HPAPI‑focused CDMO that delivers proven containment, rigorous quality, and end‑to‑end expertis

  4. Fermentation Development And Manufacturing 5/19/2026

    Scale microbial fermentation from preclinical to 40,000 L GMP with integrated biocatalysis and downstream processing. Explore Curia's full capabilities.

  5. Quality At Scale: Biologics Development And Manufacturing 5/18/2026

    886+ biologics batches. 12 commercial molecules. Proven scale-up from IND to commercialization. See how a global CDMO network protects quality at every stage.

  6. Effect of Shelf Cooling Rate on the Nucleation Temperature of Ice Monitored Using Thermocouples and Wireless Temperature Sensors 5/14/2026

    Freezing conditions shape ice structure, mass transfer resistance, and drying efficiency. Data shows how cooling rate, vial size, and nucleation interact to optimize freeze-drying.

  7. Expanding Global API Manufacturing Capacity In Dalian 5/12/2026

    Growing capacity and advanced processes support small‑molecule programs from development through commercialization with reliable, scalable manufacturing.

  8. From 51% Yield To 87% With Targeted Impurity Removal 5/7/2026

    Targeted impurity identification and purification redesign dramatically improved yield, reduced process complexity, and enabled reliable API supply for Phase II clinical development.

  9. Overcoming Product Instability And Improving Yield 5/7/2026

    Early identification of hidden product instability enabled rapid process adjustments, improving yield and keeping a preclinical toxicology program on track despite challenging reaction conditions.

  10. Producing Quality APIs At Scale 5/7/2026

    Targeted process optimization transformed an early‑phase API with yield and impurity challenges into a scalable, high‑quality manufacturing process ready to support ongoing drug development.